| Schedule of Segment information |
When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM: | | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Program expenses related to clinical-stage product candidates | | $ | (10,707,646) | | $ | (4,228,642) | | $ | (26,286,245) | | $ | (8,445,857) | Program expenses related to preclinical and discovery programs | | | (146,915) | | | (49,714) | | | (343,909) | | | (80,313) | Program expenses related to clinical manufacturing candidates | | | (144,264) | | | - | | | (415,094) | | | - | Personnel-related expenses (including stock-based compensation) | | | (2,484,630) | | | (1,496,642) | | | (3,758,951) | | | (2,894,516) | General and administrative professional and consultant fees | | | (668,764) | | | (292,649) | | | (1,159,339) | | | (737,514) | Other segment items1 | | | (225,493) | | | (203,806) | | | (426,357) | | | (395,934) | Interest income | | | 160,233 | | | 191,395 | | | 298,033 | | | 379,007 | Other non-cash income (expense) items2 | | | (603,336) | | | (140,000) | | | (335,336) | | | 418,000 | Net Loss | | $ | (14,820,815) | | $ | (6,220,058) | | $ | (32,427,198) | | $ | (11,757,127) |
1 Other segment items included in net loss include insurance expenses, rent expense, information technology expenses, listing/printing fees, warrant commissions and other miscellaneous expenses.
2 Other non-cash income (expense) items include the change in fair value of our liability classified warrants and expenses and fees incurred from issuance of warrants.
|